Please assess the completion status of the following clinical trial:

Trial Title: Sildenafil to Increase Exercise Capacity in Individuals With Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* IPF, diagnosed according to the American Thoracic Society (ATS) and European Respiratory Society (ERS) consensus statement (with or without surgical lung biopsy)~* Pulmonary hypertension, defined as mean pulmonary artery pressure (MPAP) greater than or equal to 25 mm Hg by right heart catheterization (RHC)~Exclusion Criteria:~* Interstitial lung disease due to conditions other than IPF~* Recent lung or upper respiratory tract infection within 4 weeks of study entry~* Acute or chronic impairment other than dyspnea (e.g., angina pectoris, intermittent claudication) limiting the ability to comply with study requirements (e.g., 6-minute walk test)~* Known hypersensitivity to sildenafil~* Known or suspected coronary artery disease (CAD)~* Unstable angina~* Nitrate use~* Known or suspected aortic stenosis (AS)~* Known or suspected heart attack, stroke, or life-threatening arrythmias within 1 month of study entry~* Severe chronic heart failure, defined as New York Heart Association (NYHA) class III/IV and/or left ventricular ejection fraction less than 25%~* Known penile deformities~* Known kidney or liver dysfunction~* Uncontrolled diabetes (blood glucose less than 60 mg/dl or greater than 300 mg/dl)~* Severe serum sodium abnormalities (serum sodium less than 130 mEq/L or greater than 150 mEq/L)~* Condition that may predispose participant to priapism (e.g., sickle cell anemia, multiple myeloma, leukemia)~* Retinitis pigmentosa~* Known or suspected idiopathic hypertrophic subaortic stenosis (IHSS)~* Low blood pressure (systolic blood pressure \[SBP\] less than 100 mm Hg or diastolic blood pressure \[DBP\] less than 50 mm Hg)~* Uncontrolled systemic high blood pressure (SBP greater than 180 mm Hg or DBP greater than 100 mm Hg)~* Cardiopulmonary rehabilitation program started within 8 weeks of study entry or likely to start prior to the conclusion of the study~* Treatment with an endothelin receptor antagonist, iloprost, epoprostenol, inhibitors of CYP3A4 (e.g., cimetidine, erythromycin, ketoconazole, itraconazole, mibefradil), protease inhibitors (e.g., amprenavir, indinavir, or ritonavir), rifampin, alpha-blockers (e.g., doxazosin), or other phosphodiesterase-5 inhibitors~* Current use of alcohol, grapefruit juice, or St. John's wort~* Pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).